Octagon Capital Advisors LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Octagon Capital Advisors LP reported 44 stock positions worth $606.1 million. Its top holding was Apellis Pharmaceuticals (APLS) at 18.2% of the portfolio, followed by Dianthus Therapeutics (DNTH, 7.5%) and Structure Therapeutics (GPCR, 7.4%). Compared with Q1 2024, it opened 3 new positions, sold out of 15, added to 13 and reduced 11. The biggest buy was Structure Therapeutics (GPCR, shares +125%) and the biggest sale an exit from Alpine Immune Sciences (ALPN).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001839435
- Portfolio Value
- $606.1M (Q2 2024)
- SEC Filing
- 0001839435-24-000005 ↗ filed Aug 14, 2024
Holdings Value
Holdings 44 stocks · $606.1M
| APLS Apellis Pharmaceuticals Inc. | 18.23% | 2,880,880 | $110.5M | Add +2.6% |
| DNTH Dianthus Therapeutics Inc. | 7.46% | 1,746,667 | $45.2M | Add +26.5% |
| GPCR Structure Therapeutics Inc. | 7.39% | 1,140,060 | $44.8M | Add +125.0% |
| INSM Insmed Inc. | 7.19% | 650,216 | $43.6M | Reduce -43.0% |
| DYN Dyne Therapeutics Inc. | 6.88% | 1,180,798 | $41.7M | Reduce -5.0% |
| AVBP Arrivent Biopharma Inc. | 5.52% | 1,803,304 | $33.5M | Reduce -7.2% |
| VRNA Verona Pharma Ltd. | 4.52% | 1,895,200 | $27.4M | Reduce -20.0% |
| CRBP Corbus Pharmaceuticals Holdi | 3.64% | 488,000 | $22.1M | Add +20.5% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.49% | 2,345,075 | $21.2M | Add +13.8% |
| BBIO Bridgebio Pharma Inc. | 2.88% | 690,000 | $17.5M | No change |
| OCUL Ocular Therapeutix Inc. | 2.74% | 2,425,000 | $16.6M | No change |
| CATX Perspective Therapeutics Inc. | 2.60% | 1,580,249 | $15.8M | New |
| MIND MEDICINE MINDMED INC | 2.56% | 2,153,000 | $15.5M | No change |
| PRAX Praxis Precision Medicines I | 1.77% | 260,000 | $10.8M | No change |
| TSHA Taysha Gene Therapies Inc. | 1.69% | 4,572,222 | $10.2M | Add +50.9% |
| EYPT Eyepoint Inc. | 1.57% | 1,093,503 | $9.5M | No change |
| TERN Terns Pharmaceuticals Inc. | 1.53% | 1,364,400 | $9.3M | Add +118.3% |
| GOSS Gossamer Bio Inc. | 1.37% | 9,187,883 | $8.3M | No change |
| VRDN Viridian Therapeutics Inc. | 1.33% | 620,000 | $8.1M | No change |
| TNYA Tenaya Therapeutics Inc. | 1.32% | 2,576,200 | $8.0M | Reduce -9.7% |
| RGLS Regulus Therapeutics Inc. | 1.26% | 4,263,701 | $7.6M | New |
| ALLOVIR INC | 1.17% | 9,800,000 | $7.1M | Add +133.3% |
| MLYS Mineralys Therapeutics Inc. | 1.16% | 600,000 | $7.0M | Add +9.1% |
| ANTX AN2 Therapeutics Inc. | 1.14% | 3,220,263 | $6.9M | Add +191.9% |
| AKRO Akero Therapeutics Inc. | 1.10% | 283,372 | $6.6M | Reduce -16.7% |
| JSPR Jasper Therapeutics Inc. | 1.08% | 287,500 | $6.5M | Reduce -42.6% |
| PEPG Pepgen Inc. | 0.99% | 376,117 | $6.0M | No change |
| VTYX Ventyx Biosciences Inc. | 0.91% | 2,391,114 | $5.5M | Add +59.3% |
| CYBIN INC | 0.83% | 18,604,650 | $5.0M | No change |
| IPSC Century Therapeutics Inc. | 0.56% | 1,333,650 | $3.4M | Add +147.0% |
| RENEO PHARMACEUTICALS INC | 0.56% | 2,250,000 | $3.4M | No change |
| SLN Silence Therapeutics PLC-ADR | 0.55% | 176,000 | $3.3M | Reduce -44.1% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.42% | 250,000 | $2.6M | No change |
| PSTX Poseida Therapeutics Inc. | 0.35% | 736,000 | $2.1M | No change |
| ELEV Elevation Oncology Inc. | 0.33% | 747,000 | $2.0M | New |
| MERSANA THERAPEUTICS INC | 0.33% | 992,000 | $2.0M | Reduce -0.8% |
| ANNX Annexon Inc. | 0.32% | 400,000 | $2.0M | Reduce -80.5% |
| FATE Fate Therapeutics Inc. | 0.28% | 520,800 | $1.7M | No change |
| NKTX Nkarta Inc. | 0.23% | 240,000 | $1.4M | No change |
| NUVB Nuvation Bio Inc. | 0.21% | 431,600 | $1.3M | Reduce -68.6% |
| ACET Adicet Bio Inc. | 0.15% | 767,799 | $929K | No change |
| RAPT THERAPEUTICS INC | 0.15% | 292,000 | $891K | No change |
| AEROVATE THERAPEUTICS INC | 0.13% | 465,440 | $773K | Add +15.3% |
| AUTL Autolus Therapeutics PLC | 0.10% | 176,000 | $612K | No change |
Options reported separately and not counted above: INSM calls ($16.8M), APLS calls ($13.4M).
Portfolio Sells Q1 2024 → Q2 2024
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −5.98 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −2.13 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −1.65 |
| ANNX Annexon Inc. | Reduce -80.5% | 0.32% | −1.46 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −1.17 |
| GLYCOMIMETICS INC | Sold out | 0.00% | −1.09 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −1.07 |
| ARWR Arrowhead Pharmaceuticals Inc. | Sold out | 0.00% | −0.87 |
| JSPR Jasper Therapeutics Inc. | Reduce -42.6% | 1.08% | −0.71 |
| VINCERX PHARMA INC | Sold out | 0.00% | −0.62 |
| PHAT Phathom Pharmaceuticals Inc. | Sold out | 0.00% | −0.59 |
| TNYA Tenaya Therapeutics Inc. | Reduce -9.7% | 1.32% | −0.50 |
| ANAB Anaptysbio Inc. | Sold out | 0.00% | −0.45 |
| SANA Sana Biotechnology Inc. | Sold out | 0.00% | −0.44 |
| NUVB Nuvation Bio Inc. | Reduce -68.6% | 0.21% | −0.40 |
| ALLO Allogene Therapeutics Inc. | Sold out | 0.00% | −0.39 |
| VERU Veru Inc. | Sold out | 0.00% | −0.32 |
| SLN Silence Therapeutics PLC-ADR | Reduce -44.1% | 0.55% | −0.28 |
| MERSANA THERAPEUTICS INC | Reduce -0.8% | 0.33% | −0.22 |
| ATYR Atyr Pharma Inc. | Sold out | 0.00% | −0.17 |
| VRNA Verona Pharma Ltd. | Reduce -20.0% | 4.52% | −0.11 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.11 |
| AKRO Akero Therapeutics Inc. | Reduce -16.7% | 1.10% | +0.05 |
| AVBP Arrivent Biopharma Inc. | Reduce -7.2% | 5.52% | +1.30 |
| DYN Dyne Therapeutics Inc. | Reduce -5.0% | 6.88% | +2.59 |
| INSM Insmed Inc. | Reduce -43.0% | 7.19% | +3.43 |
Portfolio Buys Q1 2024 → Q2 2024
| GPCR Structure Therapeutics Inc. | Add +125.0% | 7.39% | +4.75 |
| CATX Perspective Therapeutics Inc. | New | 2.60% | +2.60 |
| DNTH Dianthus Therapeutics Inc. | Add +26.5% | 7.46% | +2.42 |
| CRBP Corbus Pharmaceuticals Holdi | Add +20.5% | 3.64% | +1.71 |
| RGLS Regulus Therapeutics Inc. | New | 1.26% | +1.26 |
| TERN Terns Pharmaceuticals Inc. | Add +118.3% | 1.53% | +1.03 |
| ALLOVIR INC | Add +133.3% | 1.17% | +0.78 |
| ANTX AN2 Therapeutics Inc. | Add +191.9% | 1.14% | +0.71 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +13.8% | 3.49% | +0.66 |
| TSHA Taysha Gene Therapies Inc. | Add +50.9% | 1.69% | +0.63 |
| ELEV Elevation Oncology Inc. | New | 0.33% | +0.33 |
| MLYS Mineralys Therapeutics Inc. | Add +9.1% | 1.16% | +0.30 |
| IPSC Century Therapeutics Inc. | Add +147.0% | 0.56% | +0.29 |
| VTYX Ventyx Biosciences Inc. | Add +59.3% | 0.91% | −0.09 |
| AEROVATE THERAPEUTICS INC | Add +15.3% | 0.13% | −1.32 |
| APLS Apellis Pharmaceuticals Inc. | Add +2.6% | 18.23% | −1.82 |
Options Activity Q1 2024 → Q2 2024
| INSM Insmed Inc. | call | New | 250,000 | $16.8M |
| APLS Apellis Pharmaceuticals Inc. | call | Add +75.0% | 350,000 | $13.4M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $1.1B | DNTH, DFTX, ABVX, COGT, ALMS |
| Q1 2026 | 29 | $903.6M | DNTH, COGT, ABVX, ALMS, DFTX |
| Q4 2025 | 26 | $798.8M | ABVX, DNTH, COGT, TSHA, GOSS |
| Q3 2025 | 25 | $640.2M | ABVX, DNTH, GOSS, COGT, AVBP |
| Q2 2025 | 29 | $455.3M | DNTH, AVBP, VRNA, TSHA, SPRY |
| Q1 2025Amended | 33 | $460.1M | APLS, DNTH, AVBP, TRVI, CNTA |
| Q4 2024 | 30 | $587.1M | APLS, AVBP, DNTH, CNTA, VRNA |
| Q3 2024 | 40 | $623.9M | APLS, VRNA, GPCR, DNTH, AVBP |
| Q2 2024 | 44 | $606.1M | APLS, DNTH, GPCR, INSM, DYN |
| Q1 2024 | 56 | $822.6M | APLS, ALPN, DNTH, VRNA, DYN |